NCT07491081 2026-03-24
EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection
Queensland Centre for Gynaecological Cancer
Phase NA Recruiting
Clinical Trials
11 trialsNCT07472140 2026-03-16
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT05827523 2026-02-13
FOCUS / KOV-04
National Cancer Center, Korea
Phase 3 Recruiting
NCT05236686 2025-11-19
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase NA Recruiting
NCT07171528 2025-09-12
KOV-02S
National Cancer Center, Korea
Phase 2 Recruiting
NCT07169396 2025-09-11
GEN_EXP_CO2021
Azienda USL Reggio Emilia - IRCCS
Recruiting
NCT06839144 2025-07-11
OC-POP-PT
Tel-Aviv Sourasky Medical Center
Phase 2 Recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT04846933 2025-01-16
DECIDER
Turku University Hospital
Phase NA Recruiting
NCT05753826 2024-02-06
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Fujian Cancer Hospital
Phase 2 Recruiting
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting